Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether pretreatment with atorvastatin protects against atrial fibrillation following off-pump coronary artery bypass graft surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

NCT02029534

Cardiothoracic Surgery Post-operative Atrial Fibrillation

UNKNOWN PHASE4

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

NCT00756886

Arrhythmia

COMPLETED NA

The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery

NCT02157337

Aortic Surgery Acute Kidney Injury

COMPLETED PHASE4

Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose

NCT01543555

Myocardial Infarction Peripheral Vascular Disease Aortic Aneurism

COMPLETED PHASE3

Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis

NCT00811330

Aortic Valve Stenosis Ventricular Hypertrophy

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation after cardiac surgery is the most common arrhythmic complication that may increase incidence of congestive heart failure, renal insufficiency, and stroke, which increase the length of hospital stay, the rates of re-hospitalization, and cost of care. Its pathogenesis is multifactorial, and its prevention and management remain suboptimal. Recently, observational evidence has suggested that patients who have undergone previous statin therapy have a lower incidence of postoperative atrial fibrillation.

The purpose of this study is to determine whether pretreatment with atorvastatin protects against atrial fibrillation following off-pump coronary artery bypass graft surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Bypass

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Atorvastatin group

Group Type EXPERIMENTAL

atorvastatin

Intervention Type DRUG

atorvastatin 20 mg/d, started 3 days before surgery

2

Control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atorvastatin

atorvastatin 20 mg/d, started 3 days before surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* consecutive patients scheduled for the elective off-pump CABG surgery

Exclusion Criteria

* prior statin use
* previous episodes of atrial fibrillation
* impaired renal function with serum creatinine \>2mg/dL
* serum aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal
* a malignancy or inflammatory disease

Eligible Sex

ALL

Accepts Healthy Volunteers

No